Please ensure Javascript is enabled for purposes of website accessibility

MediPharm Australia Subsidiary Signs Its First European Private-Label Supply Deal

By Eric Volkman – May 15, 2020 at 8:32PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company links up with U.K.-based pharmaceutical supply-chain specialist Therismos.

Cannabis-extraction company MediPharm Labs (MEDIF -0.79%) has signed its first European "white label" supply deal. The Canada-based company announced that its MediPharm Australia subsidiary has entered into such an agreement to provide a raft of cannabis oil products to Therismos, a U.K.-based pharmaceutical supply-chain company. The agreement will be in force for three years; the financial particulars were not provided.

"White label" means that a producer supplies goods for another company to package as its own brand. MediPharm Australia received a license in late 2019 to produce cannabis extracts, and recently received Good Manufacturing Practices (GMP) certification for related products. That certification is mutually recognized by European Union authorities, even though it's an Australian producer. It's often required for cannabis products in that market.

Cannabis extract in a jar.

Image source: Getty Images.

Therismos is owned by cannabidiol (CBD) products maker Cannaray, which, like its subsidiary, is based in the U.K. By owning Therismos, the company has access to numerous European countries, as the business unit is licensed to import and distribute legal medications in that region.

"Cannaray is the gold standard in its growing part of the European market and to be chosen as their white-label partner is a coup for MediPharm Labs Australia," the latter marijuana company wrote in the press release trumpeting the deal.

MediPharm cited research from specialty analysis company Prohibition Partners forecasting that the overall European legal market could reach as much as the equivalent of $2.5 billion by 2024. That would be more than eight times the current estimated level of roughly $300 million.

Investors seem to be impressed by this deal and its potential. On Friday, they bid up MediPharm shares by over 11%, far outpacing the gains of the wider stock market.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

MediPharm Labs Corp. Stock Quote
MediPharm Labs Corp.
$0.05 (-0.79%) $0.00

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.